NCBI GenBank accession numbers for the sequences reported here are: KY713228 (SC007); KY713229 (SC008); KY713230 (SC013); KY713231 (SC015); KY713232 (SC017); KY713233 (SC022); KY713234 (SC062); KY713235 (SC085); KY713236 (SHE001); KY713237 (gag gene SC012); KY713238 (gag gene SC018); KY713239 (gag gene SC061); KY713240 (gag gene SC063); KY713241 (gag gene SC064); KY713242 (gag gene SC065); KY713243 (gag gene SC072); KY713244 (gag gene SC073); KY713245 (gag gene SC019); KY713246 (env gene SC019); KY713247 (gag gene SC023); KY713248 (env gene SC023).

Introduction {#sec001}
============

Characterising the genetic composition of HIV-1 circulating in different geographical locales represents a significant undertaking, with implications for vaccine design, treatment efficacy regimes and understanding the molecular epidemiology of transmitted variants in target populations, with group M subtypes (A-K) and circulating recombinant forms (CRFs) comprising the majority of the genotypes in global circulation. HIV-1 clade C infections represent approximately half of the total HIV-1 infections worldwide, being the majority variant in Southern Africa and the Indian subcontinent \[[@pone.0188603.ref001]\]. HIV-1 clade C therefore represents a significant target for vaccine efforts. We were interested in determining the specific variants of HIV-1 clade C circulating in a cohort of HIV-1-infected individuals in Bengaluru, southern India, using deep sequencing approaches. Previously, whole genome recovery of HIV-1 RNA from plasma using a pan-HIV-1 amplification strategy and next generation sequencing (NGS) and bioinformatics analyses has been reported \[[@pone.0188603.ref002]--[@pone.0188603.ref004]\], providing fresh insight on HIV-1 variation by taking into account many under-represented HIV-1 variants and recombinant forms in a given host.

In this study, we describe modifications of the whole genome amplification protocol described by Gall *et al* \[[@pone.0188603.ref004]\] applied to clinically-relevant plasma viruses and a bioinformatics framework in the form of a bespoke pipeline, to amplify HIV-1 genomes from Indian clinical isolates and assemble them reliably post-NGS sequencing. Further, we describe a phylogenetic analysis of these Indian HIV-1 sequences using this pipeline for the first time, as either whole genome sequences or *gag* genes to determine the relationship with the diversity of HIV-1 clade C infections worldwide.

Materials and methods {#sec002}
=====================

Clinical details {#sec003}
----------------

This study was conducted according to the principles expressed in the Declaration of Helsinki. This study was approved by the Ethical Review Committee of St. John's Medical College Hospital, Bengaluru, India (Ref no: 55/2015). Patients were included in this study after obtaining written consent. Relevant clinical information was documented in a pro forma and 30 ml of EDTA-anticoagulated peripheral blood was collected by venipuncture. A total of twenty subjects confirmed HIV seropositive (by the standard HIV I & II ELISA test and western blot) with known CD4^+^ T-cell counts and plasma HIV viral loads (Roche diagnostics, Germany) were studied (see [Table 1](#pone.0188603.t001){ref-type="table"}). Sixteen out of twenty subjects with no prior history of treatment with antiretroviral drugs \[antiretroviral treatment (ART)-naïve\] or post-exposure prophylaxis were included and were confirmed to be TB negative. Four out of the twenty HIV positive subjects (SHE001, SC007, SC019 and SC062) were diagnosed with pulmonary and/or extrapulmonary tuberculosis (TB). A diagnosis of pulmonary TB (SHE001) was ascertained by sputum smear microscopy and culture. Standard smear grading of 1+, 2+ and 3+ was used to ascertain the bacterial burden. Smear-negative cases of pulmonary TB cases were diagnosed and classified by the treating clinician from plain chest radiographs as per the Revised National Tuberculosis Control Program (RNTCP) standards. A diagnosis of extra-pulmonary TB (SC007, SC019 and SC062) was established from tissue specimens by Ziehl-Neelsen staining for detection of acid-fast bacilli in tissue samples (obtained as surgical specimens/biopsies/fine-needle aspiration specimens). The RNTCP-approved Nucleic-Acid Amplification Test (NAAT) GeneXpert MTB/Rif of tissue sample was used for confirmation of this diagnosis. Subjects SC007 and SC019 had received treatment for either TB and /or HIV. SC007 was treated for TB (Anti-Tubercular/Tuberculosis Therapy/Treatment (ATT) but ART-naïve) for 52 days, whereas SC019 had completed 6 months of treatment for both TB and HIV prior to blood collection for this study. Of the 20 samples studied, 65% were male; the median age was 33 years (range 24--51); median CD4^+^ T-cell count at the time of study was 463.5 cells/mm^3^ (range 99--853); and the median viral load was 103,300 copies/ml (range 5,978--3,330,000 copies/ml). The correlation between CD4^+^ T-cell count and viral load for each sample is depicted in Figure A in [S1 File](#pone.0188603.s001){ref-type="supplementary-material"}.

10.1371/journal.pone.0188603.t001

###### Clinical data.

![](pone.0188603.t001){#pone.0188603.t001g}

  S. No.   Sample   Age   Sex   Patient Category and Therapy              Type and site of TB                     Date of viral RNA isolation   CD4 count (cells/mm^3^)   Viral Load (copies/ml)
  -------- -------- ----- ----- ----------------------------------------- --------------------------------------- ----------------------------- ------------------------- ------------------------
  1        SHE001   45    M     HIV+TB+ (Treatment Naïve)                 Pulmonary TB, suspected intestinal TB   16-04-2015                    773                       138000
  2        SC007    26    M     HIV+TB+ (ATT 52 days and ART-naïve)       Extra pulmonary TB, TB lymphadenitis    05-05-2015                    510                       725000
  3        SC008    49    M     HIV+ ART-naïve                            None                                    20-05-2015                    389                       2980000
  4        SC012    34    F     HIV+ ART-naïve                            None                                    25-05-2015                    582                       14100
  5        SC013    30    F     HIV+ ART-naïve                            None                                    28-05-2015                    510                       120000
  6        SC015    30    M     HIV+ ART-naïve                            None                                    29-05-2015                    415                       63000
  7        SC017    45    M     HIV+ ART-naïve                            None                                    01-06-2015                    475                       108000
  8        SC018    31    M     HIV+ ART-naïve                            None                                    02-06-2015                    382                       9010
  9        SC019    34    M     HIV+TB+ (Treated for both for 6 months)   Extra pulmonary TB, Abdominal TB        06-02-2015                    267                       347000
  10       SC022    42    F     HIV+ ART-naïve                            None                                    08-06-2015                    853                       39900
  11       SC023    49    M     HIV+ ART-naïve                            None                                    08-06-2015                    583                       98600
  12       SC061    30    F     HIV+ ART-naïve                            None                                    31-08-2015                    452                       80900
  13       SC062    51    M     HIV+TB+ (Treatment Naïve)                 Extra pulmonary TB, Lymph node          03-09-2015                    167                       752000
  14       SC063    28    F     HIV+ ART-naïve                            None                                    07-09-2015                    158                       81600
  15       SC064    35    M     HIV+ ART-naïve                            None                                    07-09-2015                    109                       3330000
  16       SC065    24    M     HIV+ ART-naïve                            None                                    08-09-2015                    497                       10800
  17       SC072    32    M     HIV+ ART-naïve                            None                                    29-09-2015                    230                       5970
  18       SC073    27    M     HIV+ ART-naïve                            None                                    29-09-2015                    581                       131000
  19       SC078    32    F     HIV+ ART-naïve                            None                                    06-10-2015                    755                       13300
  20       SC085    42    F     HIV+ ART-naïve                            None                                    03-11-2015                    99                        368000

Viral RNA isolation {#sec004}
-------------------

Viral RNA was purified from 1 ml of EDTA-treated plasma using the QIAamp viral RNA mini-kits (Qiagen, Cat \# 52906) as per manufacturer protocol with some modifications. Instead of the recommended 140 μl, 1 ml of EDTA-treated plasma was processed in a single QIAamp Mini column and RNA was eluted in two batches of 40 μl of elution buffer each. 10 μl aliquots of purified plasma RNA were stored at -20°C for immediate use (less than 2 hours); long-term storage of RNA was at -80°C.

Primer design and one-step RT-PCR {#sec005}
---------------------------------

The strategy adopted was to develop the pan-HIV-1 primer approach for the putative amplification of HIV-1 genomes of all major groups (M, N and O), their subtypes and recombinants as previously reported \[[@pone.0188603.ref004]\]. Initial analysis of field samples from the Indian cohort suggested modifications of primers to improve amplification efficiency and coverage of the *gag-pol* region were required. Further modifications were introduced based on consensus C-clade genome sequences retrieved from the Los Alamos HIV Sequence Database and an extended amplicon strategy adopted (summarized in Figure B in [S1 File](#pone.0188603.s001){ref-type="supplementary-material"}). Using the primers shown in [Table 2](#pone.0188603.t002){ref-type="table"}, one-step RT-PCRs were performed to derive overlapping amplicons of 1.9 kb, 1.1 kb, 1.4 kb, 1.7 kb, 3 kb, and 3.5 kb using SuperScript III One-Step RT-PCR with Platinum *Taq* DNA High Fidelity Polymerase kits (Invitrogen, Cat \# 12574--035). Each 25 μl reaction mixture contained 12.5 μl reaction mix (2 x), 4.5 μl RNase-free water, 1 μl each of each primer (conc. 20 nmol/μl), 1 μl SuperScript III RT/ Platinum Taq High Fidelity mix and 5 μl of template RNA. Cycling conditions were 50°C for 30 min; 94°C for 2 min; 35 cycles of 94°C for 15 sec, 58°C for 30 sec, and 68°C for 4 min 30 sec; and, finally, 68°C for 10 min. Amplicon quality was verified by agarose gel electrophoresis.

10.1371/journal.pone.0188603.t002

###### Primers used in this study.
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  ----------------------------------------------------------------------------------------------------------------------------------
  Amplicon Name   Primer Sequence                          Coordinates on HXB2 genome                        Reference
  --------------- ---------------------------------------- ------------------------------------------------- -----------------------
  Amp1            `Pan-HIV-1F: AGCCYGGGAGCTCTCTG`\         26--1953 (1928 bp)                                Gall et al., JCM 2012
                  `Pan-HIV-1R: CCTCCAATTCCYCCTATCATTTT `                                                     

  Amp2 (1F&1R)    `HIV-A2-SE-F1: AgTATgggCAAgCAgggAgCT`\   891-2051(1160 bp; overlap with Amp1: 1062 bp)     This study
                  `HIV-A2-SE-R1: TgTCCTTCCTTTCCACATTTCC`                                                     

  Amp3 (2F&3R)    `HIV-A2-SE-F2: gATgACAgCATgTCAgggAgT`\   1827--3281 (1454 bp; overlap with Amp2: 224 bp)   This study
                  `HIV-A2-SE-R3: TATAggCTgTACTgTCCATTA`                                                      

  Amp4 (4F&4R)    `HIV-A2-SE-F4: CTTCCACAgggATggAAggAT`\   2994--4767 (1773 bp; overlap with Amp3: 287 bp)   This study
                  `HIV-A2-SE-R4: CTgCCATTTgTACTgCTgTCTT`                                                     

  Amp5            `Pan-HIV-3F: TTAAAAGAAAAGGGGGGATTGGG`\   4329--7394 (3066 bp; overlap with Amp4: 438 bp)   Gall et al., JCM 2012
                  `Pan-HIV-3R: TGGCYTGTACCGTCAGCG`                                                           

  Amp6            `Pan-HIV-4F: CCTATGGCAGGAAGAAGCG`\       5513--9063 (3551 bp; overlap with Amp5:1881 bp)   Gall et al., JCM 2012
                  `Pan-HIV-4R: CTTWTATGCAGCWTCTGAGGG`                                                        
  ----------------------------------------------------------------------------------------------------------------------------------

Illumina sequencing {#sec006}
-------------------

Massive parallel sequencing of the pooled amplicons was carried out on an Illumina NextSeq 500 analyser. Library preparation was performed at Genotypic Technology's Genomics facility following Nextera XT DNA Library Preparation protocol (Cat \#FC-131-1024). 1 ng of Qubit-quantified genomic DNA was tagmented (fragmented and tagged) using Amplicon Tagment Mix provided in the Nextera XT Kit. The adapter tagged DNA was subjected to 12 cycles of indexing-PCR \[72°C for 3 min followed by denaturation at 95°C for 30 sec, cycling (95°C for 10 sec, 55°C for 30 sec, 72°C for 30 sec) and 72°C for 5 min\] to enrich the adapter-tagged fragments. The PCR product was purified using HighPrep beads (Magbio Genomics, \#AC-60050). Quantification and size distribution of the prepared libraries were determined using Qubit fluorometer and the Agilent D1000 TapeStation respectively according to the manufacturer's instructions.

Bioinformatics {#sec007}
--------------

### QC and genome assembly {#sec008}

Raw reads generated from the Illumina machine were subjected to quality assessment using FastQC \[[@pone.0188603.ref005]\] and Trimmomatic v0.36 \[[@pone.0188603.ref006]\]. Based on per base quality score and k-mer presence, sequences were trimmed 10 bases at the 5'-end and five bases at 3'-end. Trimmed reads were mapped using bowtie2 \[[@pone.0188603.ref007]\] (default parameters) onto 2870 complete HIV-1 genomes to identify the closest reference. HIV-1 mapped reads were extracted and *de novo* assembled using IVA (Iterative Virus Assembler) \[[@pone.0188603.ref008]\]. IVA-assembled contigs were used as input for PRICE (Paired-Read Iterative Contig Extension) \[[@pone.0188603.ref009]\], with default options. PRICE uses incomplete assemblies of the clinical isolate genome and extends the contigs to fill the gaps iteratively. We ran PRICE for 10 iterations, choosing all contigs above 1000 bases at each cycle as templates for the next cycle. In nine cases, we obtained near complete genome assemblies (size \> 8.5 kb) using this strategy and the remaining eleven cases could be assembled to obtain the *gag* gene owing to inadequate coverage of reads. In two cases, we assembled both *gag* and *env* genes but did not have enough read support to complete the whole genome. The genomes were made into their own consensus sequence using samtools \[[@pone.0188603.ref010]\] and bcftools \[[@pone.0188603.ref011]\].

### Phylogenetic analyses {#sec009}

HIV-1 reference sequences were downloaded from the Los Alamos HIV Sequence Database \[[@pone.0188603.ref012]\] for phylogenetic analyses. Multiple sequence alignment was performed using MUSCLE \[[@pone.0188603.ref013]\] (default parameters) and phylogenetic trees were generated via maximum likelihood (ML) under the general time-reversible with gamma-distributed rate heterogeneity among sites (GTR+Γ) evolutionary model using RAxML v8.2.10 \[[@pone.0188603.ref014]\]. Trees were visualized with MEGA 7 \[[@pone.0188603.ref015]\]. The presence of intersubtype recombination was initially checked with Recombination Identification Program (RIP) \[[@pone.0188603.ref016]\], with subsequent analysis of the mosaic structure with the bootscanning method implemented in Simplot v3.5.1 \[[@pone.0188603.ref017]\]. For SNP-based phylogenetic tree, the HIV-1 specific filter reads for each sample were trimmed (adaptor/transposon sequence, 5' \< Q10 and 3' \<Q20) and clipped for an average quality score of 20 using Trimmomatic v0.36. QC-ed reads were mapped using Bowtie2 and duplicates marked using Picard MarkDuplicates \[[@pone.0188603.ref018]\]. SNP/InDels were saved in VCF format using samtools and bcftools. In order to include multiple reference sequences for a SNP-based phylogenetic tree, multiple sequence alignment among the reference was carried out with MUSCLE and corresponding bases (indicated as SNP/InDel by vcftools \[[@pone.0188603.ref019]\]) against each reference were extracted and concatenated using in-house R-scripts. The SNPs and InDels were concatenated for each sample following the same order of sequences in each case.

Results {#sec010}
=======

Amplicon recovery and protocol optimization {#sec011}
-------------------------------------------

Adaptation of the 4-amplicon strategy to recover near full-length HIV-1 genomes to a 6-amplicon strategy (Figure B in [S1 File](#pone.0188603.s001){ref-type="supplementary-material"}) for large-scale HIV-1 genome sequencing improved recovery of HIV-1 gene fragments from the Bengaluru cohort. While providing enhanced recovery of viral strains circulating in this population, amplification efficiency remained variable with some isolates, which appeared independent of baseline viral load status. Amplicons for each primer-pair, pooled in equimolar concentrations based upon NanoDrop readings, resulted in more than 1 million reads for each sample (minimum 30,000 reads per amplicon).

Initial de novo assembly and extension {#sec012}
--------------------------------------

In order to assemble a viable HIV-1 genome and enhance the potentially unique nature of each clinical isolate, we followed a two-step process involving *de novo* assembly using IVA (step 1) and PRICE (step 2). Extracted reads were mapped onto a consensus C-clade genome with the resulting read coverage for each sample shown in [Table 3](#pone.0188603.t003){ref-type="table"}. SC012, SC018, SC019, SC023, SC061, SC063, SC064, SC065, SC072, SC073 and SC078 were analyzed across *gag* as a result of low coverage downstream of the *pol* gene.

10.1371/journal.pone.0188603.t003

###### Summary of NGS results for each viral isolate.
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  ---------------- ----------- ------------------------------- ------------------------------------ --------------------- ---------------------- ----------------------------------------------- --------- ----------- ----------- -------- --------
  Whole Genome                                                                                                                                                                                                                              
                                                                                                                                                 Read Count for each primer used in this study                                              
  Sl.No.           Sample ID   Total No. of paired-end reads   Percentage of HIV-1 specific reads   Contigs After PRICE   Length of the contig   Amp1                                            Amp2      Amp3        Amp4        Amp5     Amp6
  1                SC007       12,048,590                      45.86%                               1                     9041                   1,081,560                                       839,188   2,560,787   2,406,795   38,537   17,069
  2                SC008       3,456,568                       16.75%                               1                     9084                   82,876                                          58,111    193,065     312,744     34,558   16,670
  3                SHE001      3,168,528                       28.06%                               1                     9114                   111,893                                         85,609    321,476     595,475     15,005   4,469
  4                SC013       2,259,720                       29.48%                               1                     9187                   439,695                                         399,894   161,808     64,259      93,514   16,011
  5                SC015       6,464,458                       2.37%                                1                     9122                   75,807                                          64,536    22,762      5,293       11,775   4,483
  6                SC017       6,119,426                       3.02%                                1                     9043                   83,658                                          79,833    52,115      68,269      1,665    443
  7                SC022       6,891,246                       8.60%                                1                     8940                   327,410                                         309,199   97,578      125,710     26,937   6,228
  8                SC062       6,649,608                       25.91%                               1                     9073                   894,930                                         846,293   354,433     258,557     55,657   29,616
  9                SC085       1,558,952                       14.98%                               1                     9117                   127,991                                         110,737   113,634     28,640      34,927   9,489
  Partial Genome                                                                                                                                                                                                                            
                                                                                                                                                 Read Count for each primer used in this study                                              
  Sl.No.           Sample ID   Total No. of paired-end reads   Percentage of HIV-1 specific reads   Contigs After PRICE   Length of the contig   Amp1                                            Amp2      Amp3        Amp4        Amp5     Amp6
  1                SC012       223,832                         1.57%                                1                     1839                   2,720                                           2,673     352         0           0        0
  2                SC018       305,190                         34.23%                               1                     2924                   62,556                                          58,685    9,208       64          198      67
  3                SC019       6,233,546                       15.60%                               2                     4959;3621              602,209                                         569,824   112,558     22,808      34,062   10,188
  4                SC023       6,185,790                       9.91%                                2                     4841;4384              481,739                                         431,574   75,507      6,475       7,109    8,795
  5                SC061       300,540                         52.14%                               2                     3076;1324              88,149                                          81,933    14,422      203         360      1,014
  6                SC063       1,720,104                       2.33%                                3                     2948;2354;1919         47,377                                          42,021    7,144       788         515      1,394
  7                SC064       168,998                         63.92%                               2                     3592;3297              61,325                                          56,149    13,412      1,328       3,570    1,346
  8                SC065       1,869,004                       2.62%                                1                     1978                   56,656                                          52,643    2,304       2           160      221
  9                SC072       156,858                         0.68%                                1                     2748                   390                                             300       66          13          0        0
  10               SC073       297,644                         15.23%                               1                     2150                   32,580                                          32,123    4,005       2           102      30
  ---------------- ----------- ------------------------------- ------------------------------------ --------------------- ---------------------- ----------------------------------------------- --------- ----------- ----------- -------- --------

IVA uses an overlap consensus layout along with iteratively aligning reads to contigs so as to minimise sequencing errors and rare variations within the quasispecies. PRICE utilises the preassembled contigs from IVA and extends iteratively, until sufficiently long contigs are produced and gaps filled. In our runs, use of PRICE allowed us to merge multiple kilobase-sized contigs ([Table 3](#pone.0188603.t003){ref-type="table"}) into a single genome-size assembly (\>8500 bases) for nine strains.

Phylogenetic analysis of the clinical samples {#sec013}
---------------------------------------------

Of the 20 Indian clinical samples, 9 yielded near full-length genomes (NFLG), with 10 further samples assembled across the complete *gag* gene. Sample SC078 had very few HIV-1 specific reads and could not be assembled across the complete *gag* gene and was therefore removed from further analyses.

Since recombinant sequences can affect node support values and topologies in a phylogenetic tree, prior to tree construction, the newly obtained sequences were checked for the presence of intersubtype recombination using RIP. These analyses indicated that one virus, SC017, was A1C recombinant and all other sequences were of homogeneous subtypes (subtype C, except SC072 *gag* sequence, which was of subtype B). ML trees were constructed based on either whole-genome ([Fig 1A](#pone.0188603.g001){ref-type="fig"}) or *gag* alone ([Fig 1B](#pone.0188603.g001){ref-type="fig"}), excluding SC017 from the analyses. Multiple sequence alignments were generated with the HIV-1 subtype references downloaded from the Los Alamos HIV Sequence Database. In order to examine the phylogenetic relationship of the subtype C viruses from Bengaluru with other subtype C viruses from India and other countries, in the whole-genome tree, all subtype C NFLG sequences from India and other Asian countries (China, Myanmar and Nepal) available at the Los Alamos database, as well as references from the 11 subtype C clusters previously identified in Africa \[[@pone.0188603.ref020]\], were included in the analysis. The ML tree generated with this alignment ([Fig 1A](#pone.0188603.g001){ref-type="fig"}) shows that the Bengaluru sequences branch within a strongly supported monophyletic clade comprising all but one Asian subtype C sequences (the only exception being one sequence from India), within which sequences from Nepal, on the one hand, and China and Myanmar on the other, group in respective sub-clusters. The Asian subtype C clade is closely related to the previously identified African C6 cluster, comprising viruses from Botswana and South Africa, which in turn forms part of a supercluster comprising six clusters (C1 through C6) associated with southern Africa \[[@pone.0188603.ref020]\]. Within the Asian subtype C clade, the Bengaluru sequences failed to group with each other, except two sequences, SC008 and SC062, which joined in a cluster supported by a 94% bootstrap value. In the *gag* tree ([Fig 1B](#pone.0188603.g001){ref-type="fig"}), in which 15 other subtype C and the two subtype B full-length *gag* sequences from India available at the Los Alamos database were included, 18 sequences from Bengaluru were of subtype C, branching within the Indian/Asian clade, with only two pairs of sequences (SC022/SC023; SC063/SC064) grouping in well supported clusters, and one was of subtype B. Both viruses sequenced only in *env* were subtype C, branching within the C~IN~ clade, in agreement with the *gag* phylogenetic tree (results not shown).

![Maximum likelihood phylogenetic trees of HIV-1 sequences from Bengaluru.\
Sequences from Bengaluru obtained in this study are labelled with red diamonds. Only bootstrap values ≥70% are shown. (a) Phylogenetic tree of NFLG sequences of subtype C. All NFLG subtype C sequences from Asia available at the Los Alamos HIV Sequence Database are included in the analysis. References of African subtype C clusters C1 through C10 \[[@pone.0188603.ref020]\] are also included and are shown compressed in triangles, as are clusters comprising sequences from China and Myanmar (C~CN-MM~) and from Nepal (C~NP~) (the last cluster comprising one sequence from India) nested within the Indian clade (C~IN~). (b) Phylogenetic tree of *gag* sequences of subtypes C and B. Fifteen randomly selected subtype C sequences and the only two subtype B sequences from India available at the Los Alamos database were included in the analysis, together with subtype references.](pone.0188603.g001){#pone.0188603.g001}

SNP based phylogenetic tree was constructed in the same way and the orientation of the samples reflects the results of the previous trees. The SNPs and InDels in each sample annotated on consensus subtype-C genome are represented in Figure C in [S1 File](#pone.0188603.s001){ref-type="supplementary-material"} and many of the variations appear to be in the *env* gene.

The mosaic structure of SC017 was analyzed by bootscanning using Indian A1 and C subtype references, together with references of subtypes B and H used as outgroups. The resulting bootscan plot ([Fig 2](#pone.0188603.g002){ref-type="fig"}) shows a complex structure with multiple breakpoints along the genome. To examine whether SC017 is related to other Indian A1C recombinant viruses, an ML phylogenetic tree was constructed with all Indian A1C recombinant NFLG sequences (only one per patient) deposited at the Los Alamos database. The tree shows clustering (75% bootstrap support) of SC017 only with one A1C recombinant, 95IN21301 (Figure D in [S1 File](#pone.0188603.s001){ref-type="supplementary-material"}). However, its mosaic structure differs substantially from that of SC017 (Figure E in [S1 File](#pone.0188603.s001){ref-type="supplementary-material"}).

![Bootscan analysis of the NFLG of SC017.\
The horizontal axis represents the position in the HXB2 genome and the vertical axis represents percent bootstrap values supporting clustering with reference sequences. Trees were constructed with the neighbor-joining method, using a window of 250 nt, sliding along the alignment in 20 nt steps.](pone.0188603.g002){#pone.0188603.g002}

NCBI GenBank accession numbers for the sequences reported here are: KY713228 (SC007); KY713229 (SC008); KY713230 (SC013); KY713231 (SC015); KY713232 (SC017); KY713233 (SC022); KY713234 (SC062); KY713235 (SC085); KY713236 (SHE001); KY713237 (*gag* gene SC012); KY713238 (*gag* gene SC018); KY713239 (*gag* gene SC061); KY713240 (*gag* gene SC063); KY713241 (*gag* gene SC064); KY713242 (*gag* gene SC065); KY713243 (*gag* gene SC072); KY713244 (*gag* gene SC073); KY713245 (*gag* gene SC019); KY713246 (*env* gene SC019); KY713247 (*gag* gene SC023); KY713248 (*env* gene SC023).

Discussion {#sec014}
==========

Here, we describe near full length genome recovery and assembly of HIV-1 from a clinical cohort in southern India using plasma-derived viral RNA, comprising recently replicating viral variants circulating in 20 HIV-1-diagnosed individuals from Bengaluru city. Overlapping amplicons using RT-PCR-based protocols and Illumina NextSeq 150 technology were used to generate *de novo* genome assemblies, optimized to enhance sequencing data/flow-through and to reflect evolution of HIV-1 genomes using phylogenetic analyses. Several universal methods for amplifying and sequencing whole HIV-1 genomes have been reported \[[@pone.0188603.ref002]--[@pone.0188603.ref004], [@pone.0188603.ref021]--[@pone.0188603.ref024]\]. However, we adapted the universal amplification protocol of Gall *et al* \[[@pone.0188603.ref004]\], where oligonucleotides were originally selected based on the large number of collated HIV-1 sequences in the Los Alamos database minimising amplification bias within highly conserved regions using bioinformatics predictions of sequence fidelity. Originally performed on 10 WHO HIV-1 genotype reference strains and 15 HIV-1 plasma RNA samples of various subtypes and CRFs an overall sensitivity of detection of 3000 HIV-1 RNA copies/ml was achieved. However, direct application of the universal primers appeared suboptimal for many field strains circulating in India, with plasma virus representing the primary source of viral RNA and we were unable to improve on the 3000 RNA copy number detection threshold; an overall 70% amplification efficiency success rate was, however, consistent with previous findings \[[@pone.0188603.ref002]\]. Interestingly, the inability to amplify from a proportion of Indian HIV-1 strains appeared independent of viral load even with re-design of primers, for example, to the *gag/pol* region making further refinement and re-design of these protocols inevitable. This is perhaps due to lack of documented circulating strains from South India, which can be used as a template for more efficient primer design and our data emphasizes significant differences in the *gag-pol* region of the circulating strains compared to the available reference genomes.

While Illumina sequencing is a stochastic process which may not attain equal coverage of all amplicons in a given pool, this could potentially be overcome by preparing individual libraries for each amplicon of every sample. However, the significant associated cost escalation precluded using this option. At least a million reads of a single library were generated per sample (comprising an equimolar pool of all 6 amplicons), resulting in \~30,000 reads per amplicon which represented a mathematical minimum requirement for downstream *de novo* genome assembly. In addition, *de novo* assemblies are not robust in assembling whole genomes from short, paired-end data with inherent gaps in sequence coverage. Mindful of these limitations, in an Indian clade C dominant population, we manually assessed read quality, assembly construction and number of iterations during assembly extension for each sample, rather than use a standard reference-based assembly approach.

The data generated extends our knowledge of HIV-1 strain characterization of viruses circulating in India reported since the 1990s, confirming that in addition to the largely subtype C predominance, subtypes A1 and B are also circulating as minor clades giving rise to A1C and BC recombinant forms \[[@pone.0188603.ref025]--[@pone.0188603.ref035]\]. Although analyses have usually been restricted to single genes, typically *gag*, *pol*, or *env*, some authors have reported sequencing of full-length proviral DNA of HIV-1 in India from cultured peripheral blood mononuclear cells \[[@pone.0188603.ref017],[@pone.0188603.ref033],[@pone.0188603.ref035]--[@pone.0188603.ref038]\], representative of both archived and replicating viral genomes. Reports of HIV-1 whole genome sequencing from plasma RNA, to identify viruses that are currently replicating and circulating in India, is however limited to one publication \[[@pone.0188603.ref002]\], in which sequences from 10 field HIV-1 samples genotypically confirmed to be subtype C strains were reported.

Phylogenetic analyses of partial or full-length genomes have shown that the great majority of HIV-1 subtype C strains from India group in a monophyletic clade \[[@pone.0188603.ref017],[@pone.0188603.ref025],[@pone.0188603.ref026],[@pone.0188603.ref030],[@pone.0188603.ref036],[@pone.0188603.ref038]--[@pone.0188603.ref041]\], designated C~IN~ \[[@pone.0188603.ref026]\], which, according to phylodynamic analyses, originated in the 1970s \[[@pone.0188603.ref041]--[@pone.0188603.ref043]\], although sporadic cases of subtype C viruses branching outside of the C~IN~ clade have been reported \[[@pone.0188603.ref006],[@pone.0188603.ref030],[@pone.0188603.ref036],[@pone.0188603.ref041]\]. Analyses of relationships with viruses from other countries indicate that the African viruses most closely related to C~IN~ are from the southern part of the continent \[[@pone.0188603.ref036],[@pone.0188603.ref041]\], and that subtype C strains circulating in China \[[@pone.0188603.ref036],[@pone.0188603.ref042],[@pone.0188603.ref044]\], Myanmar \[[@pone.0188603.ref042]\], Nepal \[[@pone.0188603.ref045],[@pone.0188603.ref046]\] and Bangladesh \[[@pone.0188603.ref047]\] derive from the Indian clade. Our ML phylogenetic trees confirm the monophyly of most Indian subtype C viruses, with all 8 NFLG and 18 *gag* subtype C viruses from Bengaluru branching within the C~IN~ clade, interspersed among other Indian viruses ([Fig 1](#pone.0188603.g001){ref-type="fig"}). Additionally, for the first time we examine the relationship of the C~IN~ clade with the previously identified African subtype C clusters \[[@pone.0188603.ref020]\], finding that it is closely related to a cluster (C6) comprising viruses from Botswana and South Africa ([Fig 1A](#pone.0188603.g001){ref-type="fig"}), which in turn groups in a supercluster (C1-C6) associated to Southern African countries, thus confirming previous reports indicating a close relationship between Indian and Southern African subtype C viruses.

Of the 18 viruses from Bengaluru characterized in the NFLG or *gag* or *env* genes, only two were of non-subtype C genetic forms: one A1C recombinant (SC017), characterized in the NFLG ([Fig 2](#pone.0188603.g002){ref-type="fig"}), and one of subtype B (SC072), characterized in *gag* ([Fig 1B](#pone.0188603.g001){ref-type="fig"}). These results are consistent with previous studies reporting subtype B and A1C viruses to be minor components of the Indian HIV-1 epidemic \[[@pone.0188603.ref017],[@pone.0188603.ref027],[@pone.0188603.ref028],[@pone.0188603.ref031]--[@pone.0188603.ref033]\]. SC017 exhibited a complex mosaic structure, with multiple breakpoints ([Fig 2](#pone.0188603.g002){ref-type="fig"}). In a phylogenetic tree, it appeared to be related to another A1C recombinant from India (Figure D in [S1 File](#pone.0188603.s001){ref-type="supplementary-material"}), although their mosaic structures were clearly different (Figure E in [S1 File](#pone.0188603.s001){ref-type="supplementary-material"}), implying that SC017 represents a unique recombinant form, as do other A1C recombinants characterized in India, which fail to cluster with each other (Figure D in [S1 File](#pone.0188603.s001){ref-type="supplementary-material"}).

The extent of genetic mixing and its detailed nature in the context of the widespread distribution of HIV-1 subtype C in India will only become apparent by more systematic and detailed sequencing studies underscoring the utility of deep sequencing approaches to identify changes in the balance of epidemiologically relevant strains and the appearance of novel recombinants. These are most likely to be detected by direct sequence recovery from plasma samples, taken as evidence of productive, systemic infection and recent replication events in an individual where novel variants and recombinant forms will be detectable. Further analysis of the nine whole genomes and historical database isolates suggests limited evolution over time where the virus appears well-adapted to its host. Similar clustering patterns obtained with whole genome or *gag* gene suggests that overall recombination frequencies are also low. However, greater confidence in depicting the emergence of low frequency variants from whole genome recovery, (e.g. SC017, HIV-1 A1C) will be attained with the ability to fully map whole mosaic genomes. These will be further illuminated by refining and developing the types of approach described in this report, and elsewhere, given the urgent need for an effective HIV vaccine which is particularly able to target subtype C infections.

Conclusions {#sec015}
===========

In conclusion, our data further indicate that Indian HIV-1 whole genome sequences converge to form a monophyletic lineage of subtype C, closely related to a southern African lineage, with sporadic cases of A1C recombinant forms exhibiting independent origins. While refinement of amplification protocols, sequencing platforms and bioinformatics tools for analysis of this kind of data are ongoing and likely to supersede the current study, application of techniques and approaches described here will benefit both the clinical management of HIV-1 patients, but will further allow a more precise description of molecular epidemiological trends and direction in specific geographical locales. Understanding complex interactions with coincident infections, such as tuberculosis or viral infections, will be facilitated by these types of approach. Such studies will benefit not only treatment approaches and regimens, but provide clearer data for vaccine design approaches when they become available.
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